

✓ Page 6, line 23, before "HB", insert --Hepatitis
B--.

✓ Page 7, line 19, delete "Engerix" and insert
therefor --ENGERIX--;

line 20, delete "Engerix" and insert
therefor --ENGERIX--;

line 24, delete "Engerix" and insert
therefor --ENGERIX--;

line 25, delete both occurrences of
"Engerix" and insert therefor --ENGERIX--;

line 28, delete "Engerix" and insert
therefor --ENGERIX--.

✓ Page 8, line 31, after first occurrence of
"sequence", insert --(SEQ ID NO:1)--, and same line, after
second occurrence of "sequence", insert --(SEQ ID NO:2)--;

line 33, after first occurrence of
"sequence", insert --(SEQ ID NO:3)--, and same line, after
second occurrence of "sequence", insert --(SEQ ID NO:4)--.

✓ Page 9, delete line 23 in its entirety and insert
therefor --(Omni-Mixer Homogenizer, Model No. 17106, OMNI
International, Waterbury, CT.--.

10
9/12/02
line 1
2/10/02
Page 10, delete "Engerix™" and insert therefor
--ENGERIX--;

delete line 15 in its entirety and insert

34 [therefor] --concentration of 3000 cells/well in--.

✓ Page 11, line 32, delete "Stat View II" and insert
therefor --STAT VIEW II--;

line 34, delete "Excel" and insert therefor
--EXCEL--.

✓ Page 12, line 9, after "after", delete "o.n." and
insert therefor --overnight--;

line 13, delete "Tween" and insert therefor
--TWEEN--, and same line, after "20", insert --

65 (polyoxyethylene sorbitan monolaurate)--.

✓ Please insert the attached Sequence Listing section
as new pages 1-4 of the Sequence Listing.

IN THE CLAIMS

✓ Please cancel claims 1-4, 13, 14, and 18 without
prejudice.

✓ Claim 5, line 4, after "No. 96052170;", insert --
and--; and

line 5, delete "substantially".

✓ Claim 6, line 4, after "No. 96052168;", insert --
and--; and

line 5, delete "substantially".

✓ Please rewrite claims 9-12, 15, and 17 amended form
as follows:

2 (Once-Amended). A pharmaceutical composition for
reducing the occurrence of HBV infections in a population of
C individuals ^{by passive immunotherapy} [the prevention] and/or [treatment of] ^{for} treating HBV infections comprising as active ingredient an
antibody in accordance with Claim ¹ ~~5~~ together with a
pharmaceutically acceptable carrier.

B⁷ *5* (Twice-Amended). A method for the treatment of
HBV infections comprising administering to an individual in
need a therapeutically effective amount of the antibody of
[antibodies according to] Claim ¹ ~~5~~ to treat HBV infection.

e *6* (Twice-Amended). A method for [the prevention of]
reducing the occurrence of HBV infections in a population of
individuals ^{by passive immunotherapy} comprising administering to [an individual] a
population of individuals an antibody [in accordance with] of
Claim ¹ ~~5~~ to [prevent further infection of the treated
individual with HBV] reduce the occurrence of HBV infections
in the population.

a

~~12~~ (Twice-Amended). A method for the diagnosis of HBV infections in a body fluid sample comprising:

(a) contacting said sample with an antibody of [any of] claim ~~1~~⁵ under conditions enabling the formation of antibody-antigen complexes;

B7
cont
(b) determining the level of antibody-antigen complexes formed[;], wherein a determination of the presence of a level of antibody-antigen complexes significantly higher than that formed in a control sample [indicating] indicates an HBV infection in the tested body fluid sample.

~~7~~¹⁵

(Twice-Amended). A pharmaceutical composition for [the prevention] reducing the occurrence of HBV infections in a population of individuals ^{by passive immunotherapy} and/or [treatment of] for treating HBV infections comprising as an active ingredient at least one antibody in accordance with claim ~~8~~¹ in combination with at least one other active ingredient being an anti viral agent.

B9
3 ~~17~~

(Twice-Amended). A method for the [prevention and/or] treatment of HBV infections comprising administering to an individual in need a therapeutically effective amount of a pharmaceutical composition according to claim ~~2~~⁷ to treat HBV infection.

Please add new claim 19 as follows:

B'10
c ~~19~~⁴. A method for reducing the occurrence of HBV infections in a population of individuals ^{by passive immunotherapy} comprising